Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
Ockeloen, Charlotte W, Raaijmakers, Aron, Hijmans-van der Vegt, Manon, Bierau, Jörgen, de Vos-Geelen, Judith, Willemsen, Annelieke ECAB, van den Bosch, Bianca JC, Coenen, Marieke JH
Published in Journal of oncology pharmacy practice (01.01.2023)
Published in Journal of oncology pharmacy practice (01.01.2023)
Get full text
Journal Article
mTOR inhibitor‐induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm
Willemsen, Annelieke E.C.A.B., Grutters, Jan C., Gerritsen, Winald R., van Erp, Nielka P., van Herpen, Carla M.L., Tol, Jolien
Published in International journal of cancer (15.05.2016)
Published in International journal of cancer (15.05.2016)
Get full text
Journal Article
Caution for interstitial lung disease as a cause of CA 15‐3 rise in advanced breast cancer patients treated with everolimus
Willemsen, Annelieke E.C.A.B., Grutters, Jan C., Gerritsen, Winald R., Tol, Jolien, Herpen, Carla M.L.
Published in International journal of cancer (15.08.2014)
Published in International journal of cancer (15.08.2014)
Get full text
Journal Article
Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor
Küsters-Vandevelde, Heidi Vn, Willemsen, Annelieke Ecab, Groenen, Patricia Jta, Küsters, Benno, Lammens, Martin, Wesseling, Pieter, Djafarihamedani, Melika, Rijntjes, Jos, Delye, Hans, Willemsen, Michel A, van Herpen, Carla Ml, Blokx, Willeke Am
Published in Acta neuropathologica communications (08.04.2014)
Published in Acta neuropathologica communications (08.04.2014)
Get full text
Journal Article